| 主权项 |
1. A method of treating a Pneumovirinae virus infection in a human in need thereof comprising administering to the human a therapeutically effective amount of a compound of formula Im:wherein:
Ar is a C2-C20 heterocyclyl group or a C6-C20 aryl group, wherein the C2-C20 heterocyclyl group or the C6-C20 aryl group is optionally substituted with 1 to 5 R6; X is —C(R13)(R14)—, —N(CH2R14)— or —NH—, or X is absent; R1 is H, —OR11, —NR11R12, —NR11C(O)R11, —NR11C(O)OR11, —NR11C(O)NR11R12, N3, CN, —NO2, —SR11, —S(O)pRa, NR11S(O)pRa, —C(═O)R11, —C(═O)OR11, —C(═O)NR11R12, —C(═O)SR11, —S(O)p(OR11), —SO2NR11R12, —NR11S(O)p(OR11), —NR11SOpNR11R12, —NR11C(═NR11)NR11R12, halogen, (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, aryl(C1-C8)alkyl, C6-C20 aryl, C2-C20 heterocyclyl, C2-C20 heterocyclyl(C1-C8)alkyl, (C3-C7)cycloalkyl or (C3-C7)cycloalkyl(C1-C8)alkyl; R2 is H, CN, NO2, halogen or (C1-C8)alkyl; R7 is H, OR11, —NR11R12, —NR11C(O)R11, —NR11C(O)OR11, —NR11C(O)NR11R12, N3, CN, NO2, —SR11, —S(O)pRa, —NR11S(O)pRa, —C(═O)R11, —C(═O)OR11, —C(═O)NR11R12, —C(═O)SR11, —S(O)p(OR11), —SO2NR11R12, —NR11S(O)p(OR11), —NR11SOpNR11R12, —NR11C(═NR11)NR11R12, halogen, (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, aryl(C1-C8)alkyl, C6-C20 aryl, C2-C20 heterocyclyl, C2-C20 heterocyclyl(C1-C8)alkyl, (C3-C7)cycloalkyl or (C3-C7)cycloalkyl(C1-C8)alkyl; R8 is H, —OR11, —NR11R12, NR11C(O)R11, —NR11C(O)OR11, —NR11C(O)NR11R12, N3, CN, NO2, —SR11, —S(O)pRa, —NR11S(O)pRa, —C(═O)R11, —C(═O)OR11, —C(═O)NR11R12, —C(═O)SR11, —S(O)(OR11), —SO2NR11R12, —NR11S(O)p(OR11), —NR11SOpNR11R12, NR11C(═NR11)NR11R12, halogen, (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, aryl(C1-C8)alkyl, C6-C20 aryl, C2-C20 heterocyclyl, C2-C20 heterocyclyl(C1-C8)alkyl, (C3-C7)cycloalkyl or (C3-C7)cycloalkyl(C1-C8)alkyl; each R11 or R12 is independently H, (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, aryl(C1-C8)alkyl, C6-C20 aryl, C2-C20 heterocyclyl, (C3-C7)cycloalkyl, (C3-C7)cycloalkyl(C1-C8)alkyl, —C(═O)Ra or —S(O)pRa; or when R11 and R12 are attached to a nitrogen they may optionally be taken together with the nitrogen to which they are both attached to form a 3 to 7 membered heterocyclic ring wherein any one carbon atom of said heterocyclic ring can optionally be replaced with —O—, —S—, —S(O)p—, —NH—, —NRa— or —C(O)—; R13 is H or (C1-C8)alkyl; R14 is H, (C1-C8)alkyl, NR11R12, NR11C(O)R11, NR11C(O)OR11, NR11C(O)NR11R12, NR11S(O)pRa, —NR11S(O)p(OR11) or NR11SOpNR11R12; and wherein each (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, aryl(C1-C8)alkyl, C6-C20 aryl, C2-C20 heterocyclyl, C2-C20 heterocyclyl(C1-C8)alkyl, (C3-C7)cycloalkyl or (C3-C7)cycloalkyl(C1-C8)alkyl of each R1, R2, R7, R8, R8′, R11 or R12 is independently, optionally substituted with one or more oxo, halogen, hydroxy, —NH2, CN, N3, —N(Ra)2, —NHRa, —SH, —SRa, —S(O)pRa, —ORa, (C1-C8)alkyl, (C1-C8)haloalkyl, —C(O)Ra, —C(O)H, —C(═O)ORa, —C(═O)OH, —C(═O)N(Ra)2, —C(═O)NHRa, —C(═O)NH2, —NHS(O)pRa, —NRaS(O)pRa, —NHC(O)Ra, —NRaC(O)Ra, —NHC(O)ORa, —NRaC(O)ORa, —NRaC(O)NHRa, —NRaC(O)N(Ra)2, —NRaC(O)NH2, —NHC(O)NHRa, —NHC(O)N(Ra)2, —NHC(O)NH2, ═NH, ═NOH, ═NORa, —NRaS(O)pNHRa, —NRaS(O)pN(Ra)2, —NRaS(O)pNH2, —NHS(O)pNHRa, —NHS(O)pN(Ra)2, —NHS(O)pNH2, —OC(═O)Ra, —OP(O)(OH)2 or Ra; each Ra is independently (C1-C8)alkyl, (C1-C8)haloalkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, aryl(C1-C8)alkyl, C6-C20 aryl, C2-C20 heterocyclyl, C2-C20 heterocyclyl(C1-C8)alkyl, (C3-C7)cycloalkyl or (C3-C7)cycloalkyl(C1-C8)alkyl wherein any (C1-C8)alkyl, (C1-C8)haloalkyl, (C2-C8)alkenyl or (C2-C8)alkynyl of Ra is optionally substituted with one or more OH, NH2, CO2H, C2-C20 heterocyclyl, and wherein any aryl(C1-C8)alkyl, C6-C20 aryl, C2-C20 heterocyclyl, (C3-C7)cycloalkyl or (C3-C7)cycloalkyl(C1-C8)alkyl of Ra is optionally substituted with one or more —OH, —NH2, CO2H, C2-C20 heterocyclyl or (C1-C8)alkyl; and p is 1 or 2; or a pharmaceutically acceptable salt thereof. |
